title: Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally.
abstract: A methanesulfonic acid ester of the aminoglycols, 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) has been found to be very effective in inducing and maintaining complete remissions in early cases of chronic myelogenous leukemia. The drug was given in daily doses of 1-2 mg/kg for remission induction and 0.5-1.0 mg/kg for remission maintenance, with dose adjustment according to blood cell counts. It induced complete remissions (normal white blood cell count and complete disappearance of splenomegaly) in all nine patients treated and has been maintaining these remissions (as well as a complete remission which was originally induced by NSC-84641 in an additional patient) for a period of 2 1/3 + to 15 1/3 + months. The only toxic effect observed occurred in two patients who had mild discomfort in the upper abdomen associated with soft stools. We need further observations, however, regarding the chronic toxic effects of this drug. The myelosuppressive effect of NSC-140117, within the dose range used, is granulocyte specific and appears less long lasting than that of busulfan.
authors.affiliation: First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hirano
authors.forename: M
authors.initials: M
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Kakizawa
authors.forename: A
authors.initials: A
authors.lastname: Morita
authors.forename: T
authors.initials: T
authors.lastname: Uetani
authors.forename: R
authors.initials: R
authors.lastname: Ohno
authors.forename: K
authors.initials: K
authors.lastname: Kawashima
authors.forename: H
authors.initials: H
authors.lastname: Nishiwaki
authors.forename: K
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008698:Mesylates / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D008698:Mesylates; C001441:improsan